Zipclav

• Extended antimicrobial coverage against H.Influenca and M.Catarrhalis in Acute otitis media
• Recommended by WHO as a treatment of choice in AECB
• Offers 96% clinical improvement in CAP
• Offers 97% clinical cure rate in ABS

Indications

• URTI
• LRTI
• SSTI
• UTI
• Dental Infections